Please find enclosed the newspaper advertisement for the Audited Standalone and Consolidated Financial Results for the quarter and financial year ended 31-03-2026 published in (i) Mumbai ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sudarshan Pharma Industries has published its audited financial results for Q4 and full year ended March 31, 2026. Standalone revenue grew significantly to Rs 20,301.77 lakh in Q4 FY26 from Rs 16,247.91 lakh in Q4 FY25, while full year standalone revenue reached Rs 67,590.29 lakh versus Rs 50,549.22 lakh in FY25, representing approximately 34% annual revenue growth. Net profit for Q4 standalone stood at Rs 954.28 lakh (vs Rs 702.68 lakh), and full year net profit was Rs 2,198.16 lakh (vs Rs 1,402.16 lakh in FY25), showing strong profitability improvement. EPS for FY26 standalone is Rs 0.91 per share compared to Rs 0.58 in FY25. Consolidated results also show similar growth trajectory with total comprehensive income for FY26 at Rs 2,337.17 lakh versus Rs 1,496.52 lakh in FY25.
The company has delivered robust double-digit growth in both revenue and profits for FY26, with standalone revenue crossing Rs 675 crore and net profit improving by over 56% year-on-year. The strong performance across standalone and consolidated segments indicates healthy operational growth and improved margins, which should be positive for shareholders.